RIVM international circular economy knowledge partner As of 7 December 2020, RIVM has become a knowledge partner of the international Platform for Accelerating the Circular Economy (PACE).
First COVID-19 vaccination in the Netherlands on 8 January 2021 If the European Medicines Agency (EMA) approves BioNTech/Pfizer’s COVID-19 vaccine next week, the first people in the Netherlands will receive the COVID-19 vaccine on Friday 8 January 2021.
Possible start of COVID-19 vaccination in early January If all goes well, the first people in the Netherlands will be vaccinated against COVID-19 in early January. The logistics operation aims to start vaccination in the week of 4 January 2021.
Increase in gonorrhoea and syphilis diagnoses The number of people who got themselves tested for a sexually transmitted infection (STI) at a Sexual Health Centre (SHC) in 2019 has remained almost the same as in 2018.
A guide for the safe reuse of diaper and incontinence materials RIVM has developed a step-by-step plan for the safe reuse of diapers and incontinence material. This plan provides recyclers and licensing authorities with tools to carry out a risk assessment.
Call for circular designers If you work on a circular solution or products, you can get lost in the complexity of quality labels, marketing strategies, advice and prohibitions.
Emphasising safety and sustainability in circular design A stronger focus on safety, health and sustainability is needed in designing circular products. When basic resources are re-used in new products, health risks should be avoided.
CleaR delivers framework for risk assessment of substances of concern in the recycling process For a successful circular economy, it is essential to improve the conditions in which materials and products are recycled once they have reached the end of their life cycle.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.